DSP and lung carcinoma: They detected a downregulation of desmoplakin in lung cancer and found that an overexpression of desmoplakin inhibited lung cancer cell proliferation, migration, and invasion and that it increased the sensitivity of lung cancer cells to anticancer-drug-induced apoptosis through the inhibition of Wnt/β-catenin signaling [135].